Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01711632 | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 737 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 20, 2025 |
| clinicaltrials |
| NCT02680795 | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes | completed | Phase 1 | 17 | Acrotech Biopharma Inc.INDUSTRY | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | completed | Phase 1 | 37 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Oct 16, 2025 | clinicaltrials |
| NCT04601831 | 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL | completed | Phase 1 / Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT02412228 | Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | completed | Phase 2 | 12 | John L. ReaganOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT02512926 | Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children(POE14-01) | completed | Phase 1 | 4 | Stanford UniversityOTHER | 2 | Oct 15, 2025 | clinicaltrials |
| NCT03118466 | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 41 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT01760226 | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies(DA-EPOCH-R) | completed | Early Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02367040 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-3) | completed | Phase 3 | 458 | BayerINDUSTRY | 37 | Oct 14, 2025 | clinicaltrials |
| NCT03515512 | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | completed | Phase 1 | 23 | Massachusetts General HospitalOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies(ELM-1) | completed | Phase 1 | 200 | Regeneron PharmaceuticalsINDUSTRY | 5 | Oct 10, 2025 | clinicaltrials |
| NCT04540796 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 147 | Janssen Research & Development, LLCINDUSTRY | 8 | Oct 10, 2025 | clinicaltrials |
| NCT01908777 | A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 47 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT03892967 | Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial | completed | N/A | 50,207 | Mayo ClinicOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05564052 | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma(VEGA) | completed | Phase 2 | 36 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 7, 2025 | clinicaltrials |
| NCT05205512 | Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial | completed | N/A | 10 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03480438 | Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab(EWALL-BOLD) | completed | Phase 2 | 52 | Goethe UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07206810 | A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients | completed | — | 419 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT01316250 | Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia | completed | N/A | 13 | American University of Beirut Medical CenterOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02201459 | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients(PETALs) | completed | Phase 3 | 200 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03680092 | Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | completed | Phase 2 | 43 | Dimitrios Tzachanis, MD PhDOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04188912 | Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study(CATCH) | completed | — | 267 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05517213 | High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma | completed | N/A | 62 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06095752 | Multiple Myeloma Prognostic Indices | completed | — | 48 | Assiut UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04609826 | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)(DHODH) | completed | Phase 1 | 153 | Janssen Research & Development, LLCINDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT04773522 | A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 15 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05153343 | Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | completed | Phase 1 / Phase 2 | 31 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05526313 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant | completed | Phase 1 | 29 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT02356159 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03731832 | Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 66 | GWT-TUD GmbHOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04810052 | Positive Activities Intervention to Improve Quality of Life in Collectivist Culture Cancer Patients and Their Caregivers | completed | N/A | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04984356 | A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | completed | Phase 1 | 28 | Allotera TherapeuticsINDUSTRY | 4 | Sep 30, 2025 | clinicaltrials |
| NCT05319587 | Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 22 | Moleculin Biotech, Inc.INDUSTRY | 2 | Sep 30, 2025 | clinicaltrials |
| NCT05470140 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | completed | Phase 1 | 9 | Allotera TherapeuticsINDUSTRY | 2 | Sep 30, 2025 | clinicaltrials |
| NCT06389357 | Retun-to-school Adaptation Program for Children With Cancer(web-based) | completed | N/A | 20 | Gazi UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05212233 | Financial Difficulty in Patients With Blood Cancer | completed | — | 218 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05238376 | Survivorship Post-HCT Optimization Program(S-POP) | completed | N/A | 16 | Duke UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06326697 | Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 32 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma(RELEVANCE) | completed | Phase 3 | 1,030 | The Lymphoma Academic Research OrganisationOTHER | 8 | Sep 25, 2025 | clinicaltrials |
| NCT05506683 | Improving Nighttime Access to Care and Treatment; Part 2- Ghana(INACT2-G) | completed | N/A | 1,239 | University of FloridaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05509439 | Home Transfusion for HEME | completed | N/A | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05565638 | PROFAST Intervention in Precursor Multiple Myeloma(PROFAST) | completed | N/A | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04318080 | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma(TIRHOL) | completed | Phase 2 | 46 | BeiGeneINDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05471700 | Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients | completed | N/A | 40 | Zhujiang HospitalOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07188428 | Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment | completed | — | 2,298 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05223920 | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | completed | Phase 2 | 81 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 7 | Sep 22, 2025 | clinicaltrials |
| NCT06358001 | EchoTip AcuCore Post-Market Clinical Study | completed | — | 183 | Cook Research IncorporatedINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 20, 2025source: clinicaltrials